It will address infections triggered by bacteria, viruses, and fungi.
Thestartups work builds on the research of the University of Iceland, which is one the companys owners.
40% off TNW Conference!
Upon completion, IN-ARMOR will move to clinical validation.
If successful, IN-ARMOR would have the potential to save long-term 107 billion in antibiotics development.
Story byIoanna Lykiardopoulou
Ioanna is a writer at TNW.
With a background in the humanities, she has a soft spot for social impact-enabling technologies.
